Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases

NCT04965597 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT04965597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04965597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
April 19, 2022
Completion date
February 18, 2026
Enrollment
40 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow failure syndrome, congenital amegakaryocytic thrombocytopenia, diamond-blackfan anemia, hematologic neoplasm with germline gata2 mutation, hematologic neoplasm with germline samd9 mutation, hematologic neoplasm with germline samd9l mutation, hereditary sideroblastic anemia, paroxysmal nocturnal hemoglobinuria, shwachman-diamond syndrome